Company news

Catalyst Pharmaceuticals, Inc. news in 2025

Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 14, 2025

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

November 23, 2025

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

November 18, 2025

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 17, 2025

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

November 3, 2025

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

November 2, 2025

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

October 21, 2025

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

October 8, 2025

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

September 30, 2025

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

August 27, 2025

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

August 26, 2025

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

August 5, 2025

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

August 5, 2025

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

August 3, 2025

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

July 21, 2025

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

June 1, 2025

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

April 29, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

April 21, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

April 7, 2025

Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

April 7, 2025

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

March 3, 2025

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 25, 2025

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

February 11, 2025

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

January 22, 2025

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

January 20, 2025

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

January 7, 2025

Calls in 2025

Decks in 2025